Ponni Sugars (Erode) Limited (NSE:PONNIERODE)
India · Delayed Price · Currency is INR | Market Cap | 2.39B |
| Revenue (ttm) | 3.65B |
| Net Income (ttm) | 157.90M |
| Shares Out | n/a |
| EPS (ttm) | 18.38 |
| PE Ratio | 15.14 |
| Forward PE | n/a |
| Dividend | 3.00 (1.05%) |
| Ex-Dividend Date | May 30, 2025 |
| Volume | 5,103 |
| Average Volume | 22,602 |
| Open | 286.00 |
| Previous Close | 278.80 |
| Day's Range | 273.90 - 286.00 |
| 52-Week Range | 267.00 - 561.00 |
| Beta | 0.05 |
| RSI | 25.43 |
| Earnings Date | Jul 18, 2025 |
About Revance Therapeutics
Ponni Sugars (Erode) Limited manufactures and sells sugar in India. It operates in two segments, Sugar and Cogeneration. The company is involved in the provision of bagasse and molasses; and cogeneration of power. It also exports its products. The company was formerly known as SPB Sugars and Chemicals Limited and changed its name to Ponni Sugars (Erode) Limited in January 2000. Ponni Sugars (Erode) Limited was incorporated in 1996 and is based in Chennai, India. [Read more]
Financial Performance
In 2024, Ponni Sugars (Erode)'s revenue was 3.59 billion, a decrease of -14.68% compared to the previous year's 4.21 billion. Earnings were 192.80 million, a decrease of -58.86%.
Financial StatementsNews
Ponni Sugars shares drop 4% on weak Q3 results
Following the results, the stock price of Ponni Sugars dropped by 4%, trading at ₹383.05 on the NSE. The decline reflects investor concerns over the company’s steep reduction in profitability despite ...
Ponni Sugars (Erode) Q3 FY25 Results: Revenue down 7% to 115.74 crore, Net Profit down 79% YoY
Ponni Sugars (Erode) Limited has announced its unaudited financial results for the quarter ended December 31, 2024, reflecting mixed performance amidst challenging market conditions. Here’s an overvie...